PKU Nutritional Composition for Brain Function via Amino Acid Competition

The patent introduces large neutral amino acids (LNAA) as intermediary substances that compete with Phe at the BBB transporter. This mediates the transport issue by providing alternative substrates that can cross the blood-brain barrier, thereby improving brain availability of Tyr and Trp without directly addressing the Phe accumulation problem. The LNAA act as competitive inhibitors that facilitate the desired outcome (improved neurotransmitter synthesis) by interfering with the harmful process (Phe transport into brain).

The patent changes the concentration parameters of specific amino acids in the diet. By increasing the concentration of Tyr, Trp, and LNAA while maintaining controlled Phe levels, the patent alters the competitive dynamics at the BBB transporter. This parameter change strategy shifts the balance in favor of beneficial amino acids entering the brain, thereby improving cognitive function while still controlling toxic Phe accumulation.

The patent applies preliminary action by supplementing with Tyr, Trp, and LNAA before cognitive deficits become severe. This proactive approach ensures that the substrates for neurotransmitter synthesis are available in advance, allowing the brain to maintain adequate neurotransmitter levels even when Phe is controlled. The preliminary provision of these amino acids prevents the development of executive functioning deficits rather than treating them after they occur.

The patent creates a composite nutritional formulation that combines multiple amino acids (Tyr, Trp, and various LNAA) in specific ratios. This composite approach addresses the multiple interconnected problems of Phe control, BBB transport competition, and neurotransmitter precursor availability. The synergistic combination of these amino acids works together to improve executive functioning while maintaining controlled plasma Phe levels.

The patent applies partial action by not requiring complete elimination of natural proteins. Instead, it provides a partial solution through targeted amino acid supplementation that addresses the specific metabolic defect in PKU. This partial approach (supplementing key amino acids rather than eliminating all proteins) makes the treatment more compliant while still achieving cognitive improvement, recognizing that complete protein elimination is unnecessarily restrictive for this specific condition.

The patent enables self-service by providing amino acids that the PKU patient's body can utilize directly for neurotransmitter synthesis. The supplemented amino acids serve the brain's needs without requiring the patient to process natural proteins through the defective PAH enzyme pathway. This self-service approach allows the body to bypass the metabolic block and directly use the provided substrates for cognitive function maintenance.